Intensity Therapeutics, Inc.
INTS Nasdaq
SEC CIK 1567264
Follow Intensity Therapeutics
Weekly email: filings, results
Net income
−$3.5M
−32.7% vs same quarter last year
EPS, diluted
−$1.09
+29.7% vs same quarter last year
Operating cash flow
−$2.5M
−4.7% vs same quarter last year
Operating income
−$3.6M
−32.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$11.6M |
| FY24 | −$16.3M |
| FY23 | −$10.5M |
| FY22 | −$7.6M |
| FY21 | - |